Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
USC appoints Dr. Mattison distinguished professor
Dr. Donald Mattison, RSI’s Senior Vice-President and Chief Medical Officer, has accepted an appointment as a University of South Carolina Health Sciences Distinguished Professor in the in…
Read News ItemRSI receives National Defence funding
RSI is pleased to be the recipient of funding through the DND IDEaS COVID-19 Challenge. Under the supervision of Emma Hartnett, RSI will be developing…
Read News ItemWillhite receives prestigious SOT award
Calvin C. Willhite, an Associate Expert with Risk Sciences International working on a range of toxicological risk issues, was just announced as the recipient of the prestigious…
Read News ItemRSI gives keynote
RSI experts Jennifer Go and Daniel Krewski, were recently invited to present a paper on maternal and child environmental heath during a global, virtual workshop originating in Foshan, Guangdong, China.
Read News Item